297 related articles for article (PubMed ID: 24717964)
1. Primary immunization of infants and toddlers in Thailand with Japanese encephalitis chimeric virus vaccine in comparison with SA14-14-2: a randomized study of immunogenicity and safety.
Feroldi E; Pancharoen C; Kosalaraksa P; Chokephaibulkit K; Boaz M; Meric C; Hutagalung Y; Bouckenooghe A
Pediatr Infect Dis J; 2014 Jun; 33(6):643-9. PubMed ID: 24717964
[TBL] [Abstract][Full Text] [Related]
2. A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea.
Kim DS; Houillon G; Jang GC; Cha SH; Choi SH; Lee J; Kim HM; Kim JH; Kang JH; Kim JH; Kim KH; Kim HS; Bang J; Naimi Z; Bosch-Castells V; Boaz M; Bouckenooghe A
Hum Vaccin Immunother; 2014; 10(9):2656-63. PubMed ID: 25483480
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children.
Janewongwirot P; Puthanakit T; Anugulruengkitt S; Jantarabenjakul W; Phasomsap C; Chumket S; Yoksan S; Pancharoen C
Vaccine; 2016 Oct; 34(44):5279-5283. PubMed ID: 27628323
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and Safety of a Booster Dose of a Live Attenuated Japanese Encephalitis Chimeric Vaccine Given 1 Year After Primary Immunization in Healthy Children in the Republic of Korea.
Kim DS; Jang GC; Cha SH; Choi SH; Kim HM; Kim JH; Kang JH; Kim JH; Kim KH; Bang J; Naimi Z; Bouckenooghe A; Bosch-Castells V; Houillon G
Pediatr Infect Dis J; 2016 Feb; 35(2):e60-4. PubMed ID: 26535878
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of a single dose of a live attenuated Japanese encephalitis chimeric virus vaccine in Vietnam: A single-arm, single-center study.
Vu TD; Nguyen QD; Tran HTA; Bosch-Castells V; Zocchetti C; Houillon G
Int J Infect Dis; 2018 Jan; 66():137-142. PubMed ID: 29081368
[TBL] [Abstract][Full Text] [Related]
6. Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12-18 months: randomized, controlled phase 3 immunogenicity and safety trial.
Feroldi E; Pancharoen C; Kosalaraksa P; Watanaveeradej V; Phirangkul K; Capeding MR; Boaz M; Gailhardou S; Bouckenooghe A
Hum Vaccin Immunother; 2012 Jul; 8(7):929-37. PubMed ID: 22777096
[TBL] [Abstract][Full Text] [Related]
7. Long-term Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine in Toddlers and Booster Response 5 Years After Primary Immunization.
Kosalaraksa P; Watanaveeradej V; Pancharoen C; Capeding MR; Feroldi E; Bouckenooghe A
Pediatr Infect Dis J; 2017 Apr; 36(4):e108-e113. PubMed ID: 28030526
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of Japanese encephalitis chimeric virus vaccine: Immune responses in children.
Chokephaibulkit K; Sirivichayakul C; Thisyakorn U; Pancharoen C; Boaz M; Bouckenooghe A; Feroldi E
Vaccine; 2016 Nov; 34(46):5664-5669. PubMed ID: 27686833
[TBL] [Abstract][Full Text] [Related]
9. Immunizing children aged 9 to 15 months with live attenuated SA14-14-2 Japanese encephalitis vaccine in Thailand.
Chotpitayasunondh T; Sohn YM; Yoksan S; Min J; Ohrr H
J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S195-203. PubMed ID: 22043776
[TBL] [Abstract][Full Text] [Related]
10. Concomitant administration of live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) and measles, mumps, rubella (MMR) vaccine: randomized study in toddlers in Taiwan.
Huang LM; Lin TY; Chiu CH; Chiu NC; Chen PY; Yeh SJ; Boaz M; Hutagalung Y; Bouckenooghe A; Feroldi E
Vaccine; 2014 Sep; 32(41):5363-9. PubMed ID: 24631095
[TBL] [Abstract][Full Text] [Related]
11. Memory immune response and safety of a booster dose of Japanese encephalitis chimeric virus vaccine (JE-CV) in JE-CV-primed children.
Feroldi E; Capeding MR; Boaz M; Gailhardou S; Meric C; Bouckenooghe A
Hum Vaccin Immunother; 2013 Apr; 9(4):889-97. PubMed ID: 23442823
[TBL] [Abstract][Full Text] [Related]
12. Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis.
Paulke-Korinek M; Kollaritsch H; Kundi M; Zwazl I; Seidl-Friedrich C; Jelinek T
Vaccine; 2015 Jul; 33(30):3600-4. PubMed ID: 26036947
[TBL] [Abstract][Full Text] [Related]
13. Modeling the long-term persistence of neutralizing antibody in children and toddlers after vaccination with live attenuated Japanese encephalitis chimeric virus vaccine.
Bouckenooghe A; Bailleux F; Feroldi E
Hum Vaccin Immunother; 2019; 15(1):72-79. PubMed ID: 30230947
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: Randomised controlled phase 3 trials.
Torresi J; McCarthy K; Feroldi E; Méric C
Vaccine; 2010 Nov; 28(50):7993-8000. PubMed ID: 20934459
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of a Live Attenuated Chimeric Japanese Encephalitis Vaccine as a Booster Dose After Primary Vaccination With Live Attenuated SA14-14-2 Vaccine: A Phase IV Study in Thai Children.
Sricharoenchai S; Lapphra K; Chuenkitmongkol S; Phongsamart W; Bouckenooghe A; Wittawatmongkol O; Rungmaitree S; Chokephaibulkit K
Pediatr Infect Dis J; 2017 Feb; 36(2):e45-e47. PubMed ID: 27846060
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a single administration of live-attenuated Japanese encephalitis vaccine in previously primed 2- to 5-year-olds and naive 12- to 24-month-olds: multicenter randomized controlled trial.
Chokephaibulkit K; Sirivichayakul C; Thisyakorn U; Sabchareon A; Pancharoen C; Bouckenooghe A; Gailhardou S; Boaz M; Feroldi E
Pediatr Infect Dis J; 2010 Dec; 29(12):1111-7. PubMed ID: 20856164
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of a live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) in children.
Chokephaibulkit K; Houillon G; Feroldi E; Bouckenooghe A
Expert Rev Vaccines; 2016; 15(2):153-66. PubMed ID: 26588242
[TBL] [Abstract][Full Text] [Related]
18. One-year immunogenicity kinetics and safety of a purified chick embryo cell rabies vaccine and an inactivated Vero cell-derived Japanese encephalitis vaccine administered concomitantly according to a new, 1-week, accelerated primary series.
Cramer JP; Jelinek T; Paulke-Korinek M; Reisinger EC; Dieckmann S; Alberer M; Bühler S; Bosse D; Meyer S; Fragapane E; Costantini M; Pellegrini M; Lattanzi M; Dovali C
J Travel Med; 2016 Mar; 23(3):. PubMed ID: 26994987
[TBL] [Abstract][Full Text] [Related]
19. A 5-year follow-up of antibody response in children vaccinated with single dose of live attenuated SA14-14-2 Japanese encephalitis vaccine: immunogenicity and anamnestic responses.
Sohn YM; Tandan JB; Yoksan S; Ji M; Ohrr H
Vaccine; 2008 Mar; 26(13):1638-43. PubMed ID: 18294743
[TBL] [Abstract][Full Text] [Related]
20. [A large-scale study on the safety and epidemiological efficacy of Japanese encephalitis (JE) live vaccine (SA14-14-2) in the JE endemic areas].
Zhou B; Jia L; Xu X
Zhonghua Liu Xing Bing Xue Za Zhi; 1999 Feb; 20(1):38-41. PubMed ID: 10682513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
